A

Correction to: Cenobamate: real-world data from a retrospective multicenter study

Journal of Neurology, vol. 271, pp. 6605

Abstract

Background Clinical trials have shown that cenobamate (CNB) is an efficacious and safe anti-seizure medication (ASM) for drug-resistant focal epilepsy.Here, we analyzed one of the largest real-world cohorts, covering the entire spectrum of epilepsy syndromes, the efficacy and safety of CNB, and resulting changes in concomitant ASMs. MethodsWe conducted a retrospective observational study investigating CNB usage in two German tertiary referral centers between October 2020 and June 2023 with followup data up to 27 months of treatment.Our primary outcome was treatment response.Secondary outcomes comprised drug response after 12 and 18 months, seizure freedom rates, CNB dosage and retention, adverse drug reactions (ADRs), and changes in concomitant ASMs.Results 116 patients received CNB for at least two weeks.At 6 months, 98 patients were eligible for evaluation.Thereof

Authors 11

  1. Stephan Lauxmann corresponding

    Hertie Institute for Clinical Brain Research · University of Tübingen

    Affiliation as printed

    Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Germany. stephan.lauxmann@uni-tuebingen.de

    Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Germany

  2. Universitätsklinikum Aachen · RWTH Aachen University

    Affiliation as printed

    Department of Epileptology and Neurology, RWTH Aachen University Hospital, Aachen, Germany

  3. Universitätsklinikum Aachen · RWTH Aachen University

    Affiliation as printed

    Department of Epileptology and Neurology, RWTH Aachen University Hospital, Aachen, Germany

  4. Hertie Institute for Clinical Brain Research · University of Tübingen

    Affiliation as printed

    Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Germany

  5. Universitätsklinikum Aachen · RWTH Aachen University

    Affiliation as printed

    Department of Epileptology and Neurology, RWTH Aachen University Hospital, Aachen, Germany

  6. Universitätsklinikum Aachen · RWTH Aachen University

    Affiliation as printed

    Department of Epileptology and Neurology, RWTH Aachen University Hospital, Aachen, Germany

  7. Universitätsklinikum Aachen · RWTH Aachen University

    Affiliation as printed

    Department of Epileptology and Neurology, RWTH Aachen University Hospital, Aachen, Germany

  8. Hertie Institute for Clinical Brain Research · University of Tübingen

    Affiliation as printed

    Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Germany

  9. University Children's Hospital Tübingen · University of Tübingen

    Affiliation as printed

    Department of Pediatric Neurology and Developmental Medicine, University Children's Hospital, Tuebingen, Germany

  10. Hertie Institute for Clinical Brain Research · University of Tübingen

    Affiliation as printed

    Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Germany

  11. Universitätsklinikum Aachen · RWTH Aachen University

    Affiliation as printed

    Department of Epileptology and Neurology, RWTH Aachen University Hospital, Aachen, Germany

Cited by 1 stored of 1

1 result

No patents citing this paper on Lens.org (checked 2026-10-06).

References 0